21st March 2022 | Pharma Updates
Labcorp receives CDSCO approval for research on an anticancer medication
CDSCO has given Labcorp permission to undertake a research comparing the anti-neoplastic medicine Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab.
NCB arrests MD of Pharma firm and four others in Telangana for exporting Tramadol to Pakistan
MD, and four other workers of a pharmaceutical firm in Telangana were arrested by NCB in Bengaluru on Friday for allegedly re-exporting Tramadol to Pakistan.
FDA has given the go ahead to Bristol-Myers Squibb's Lag-3 medication
The medicine, known as relatlimab, was created by Bristol Myers Squibb and is approved for individuals with metastatic melanoma or melanoma that cannot be treated with surgery.
According to a study, lithium may reduce the risk of dementia
Although the overall number of patients who took lithium was small, the analysis revealed that individuals who received lithium were less likely to acquire dementia than those who did not.
SPIMACO has partnered with Vifor Pharma to manufacture Ferinjectin US
The first intends to localise the production of Ferinject for the treatment of iron deficiency, while the second aims to manufacture and sell ferric carboxymaltose through SPIMACO.
Athira Pharma presents a study overview from Fosgonimeton's ACT-AD Phase 2 trial
Athira Pharma has announced the study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of fosgonimeton, in study participants with mild-to-moderate Alzheimer’s disease.
Orthocell's Remplir nerve healing device has been approved by Australian regulators
Remplir is the world’s first biological scaffold, created by an Australian team of researchers to imitate the outer layer of the peripheral nerve and promote high-quality nerve healing.
Apellis aiming to be the first to receive FDA approval for rare visual condition
Apellis Pharmaceuticals has more clinical evidence that shows their medicine is effective against geographic atrophy, a rare vision loss illness for which there is no FDA-approved treatment.
With new treatment options for cervical cancer, it's more important to consider individual patient characteristics
In 2021, the FDA will approve two new cervical cancer drugs, a figure that moderator Bradley Monk, MD, FACS, FACOG, described as “unprecedented. “
In advanced or recurrent endometrial cancer, Selinexor proves its worth
When used as maintenance therapy for patients with advanced or recurrent endometrial cancer who responded to front-line chemotherapy, selinexor (Xpovio) improved outcomes.
